BACKGROUND: Genetic markers in the serotonin transporter are associated with panic disorder (PD). The associated polymorphisms do not include the serotonin transporter-linked polymorphic region and display no obvious functional attributes. A common polymorphism (rs3813034) occurs in one of the two reported polyadenylation signals for the serotonin transporter and is in linkage disequilibrium with the PD-associated markers. If functional, rs3813034 might be the risk factor that explains the association of the serotonin transporter and PD. METHODS: Quantitative polymerase chain reaction on human brain samples (n = 65) and lymphoblast cultures (n = 71) was used to test rs3813034 for effects on expression of the polyadenylation forms of the serotonin transporter. rs3813034 was also tested for association in a sample of PD cases (n = 307) and a control sample (n = 542) that has similar population structure. RESULTS: The balance of the two polyadenylation forms of the serotonin transporter is associated with rs3813034 in brain (p < .001) and lymphoblasts (p < .001). The balance of the polyadenylation forms is also associated with gender in brain only (p < .05). Association testing of rs3813034 in PD identified a significant association (p = .0068) with a relative risk of 1.56 and 1.81 for the heterozygous and homozygous variant genotypes, respectively. CONCLUSIONS: rs3813034 is a functional polymorphism in the serotonin transporter that alters the balance of the two polyadenylation forms of the serotonin transporter. rs3813034 is a putative risk factor for PD and other behavioral disorders that involve dysregulation of serotonergic neurotransmission. 2010 Society of Biological Psychiatry. Published by Elsevier Inc. All rights reserved.
BACKGROUND: Genetic markers in the serotonin transporter are associated with panic disorder (PD). The associated polymorphisms do not include the serotonin transporter-linked polymorphic region and display no obvious functional attributes. A common polymorphism (rs3813034) occurs in one of the two reported polyadenylation signals for the serotonin transporter and is in linkage disequilibrium with the PD-associated markers. If functional, rs3813034 might be the risk factor that explains the association of the serotonin transporter and PD. METHODS: Quantitative polymerase chain reaction on human brain samples (n = 65) and lymphoblast cultures (n = 71) was used to test rs3813034 for effects on expression of the polyadenylation forms of the serotonin transporter. rs3813034 was also tested for association in a sample of PD cases (n = 307) and a control sample (n = 542) that has similar population structure. RESULTS: The balance of the two polyadenylation forms of the serotonin transporter is associated with rs3813034 in brain (p < .001) and lymphoblasts (p < .001). The balance of the polyadenylation forms is also associated with gender in brain only (p < .05). Association testing of rs3813034 in PD identified a significant association (p = .0068) with a relative risk of 1.56 and 1.81 for the heterozygous and homozygous variant genotypes, respectively. CONCLUSIONS:rs3813034 is a functional polymorphism in the serotonin transporter that alters the balance of the two polyadenylation forms of the serotonin transporter. rs3813034 is a putative risk factor for PD and other behavioral disorders that involve dysregulation of serotonergic neurotransmission. 2010 Society of Biological Psychiatry. Published by Elsevier Inc. All rights reserved.
Authors: Ole F Olesen; Bente Bennike; Elsebet S Hansen; Pernille Koefoed; David P Woldbye; Tom G Bolwig; Erling Mellerup Journal: Psychiatr Genet Date: 2005-09 Impact factor: 2.458
Authors: L J Strug; R Suresh; A J Fyer; A Talati; P B Adams; W Li; S E Hodge; T C Gilliam; M M Weissman Journal: Mol Psychiatry Date: 2008-07-29 Impact factor: 15.992
Authors: Ahmad R Hariri; Venkata S Mattay; Alessandro Tessitore; Bhaskar Kolachana; Francesco Fera; David Goldman; Michael F Egan; Daniel R Weinberger Journal: Science Date: 2002-07-19 Impact factor: 47.728
Authors: Jerzy Samochowiec; Anna Hajduk; Agnieszka Samochowiec; Jan Horodnicki; Genowefa Stepień; Anna Grzywacz; Jolanta Kucharska-Mazur Journal: Psychiatry Res Date: 2004-08-30 Impact factor: 3.222
Authors: A S Howe; H N Buttenschøn; A Bani-Fatemi; E Maron; T Otowa; A Erhardt; E B Binder; N O Gregersen; O Mors; D P Woldbye; K Domschke; A Reif; J Shlik; S Kõks; Y Kawamura; A Miyashita; R Kuwano; K Tokunaga; H Tanii; J W Smoller; T Sasaki; D Koszycki; V De Luca Journal: Mol Psychiatry Date: 2015-09-22 Impact factor: 15.992
Authors: Catherine A Hartley; Morgan C McKenna; Rabia Salman; Andrew Holmes; B J Casey; Elizabeth A Phelps; Charles E Glatt Journal: Proc Natl Acad Sci U S A Date: 2012-03-19 Impact factor: 11.205
Authors: YoneJung Yoon; Morgan C McKenna; David A Rollins; Minseok Song; Tal Nuriel; Steven S Gross; Guoqiang Xu; Charles E Glatt Journal: Proc Natl Acad Sci U S A Date: 2013-06-24 Impact factor: 11.205
Authors: Ryan L Subaran; Ardesheer Talati; Steven P Hamilton; Phillip Adams; Myrna M Weissman; Abby J Fyer; Susan E Hodge Journal: Psychiatr Genet Date: 2012-12 Impact factor: 2.458
Authors: Jeanne E Savage; Omari McMichael; Eugenia I Gorlin; Jessica R Beadel; Bethany Teachman; Vladimir I Vladimirov; John M Hettema; Roxann Roberson-Nay Journal: Biol Psychol Date: 2015-04-22 Impact factor: 3.251